TY - JOUR
T1 - Spinal muscular atrophy
T2 - Classification, diagnosis, management, pathogenesis, and future research directions
AU - Kostova, Felina V.
AU - Williams, Virginia C.
AU - Heemskerk, Jill
AU - Iannaccone, Susan
AU - DiDonato, Christine
AU - Swoboda, Kathryn
AU - Maria, Bernard L.
PY - 2007/8
Y1 - 2007/8
N2 - Spinal muscular atrophy is an autosomal recessive neurodegenerative disorder that affects the motor neurons responsible for movement of the proximal muscles of the trunk and body. To date, the disease can be classified into 3 main categories based on severity and age of onset. During the October 18th symposium held in Pittsburgh, Pennsylvania, researchers met to (1) describe current diagnostic strategies, (2) discuss recent thoughts on pathogenesis, (3) review current therapies and clinical trials, and (4) define future research directions. In her opening remarks, Dr Story Landis, director of the National Institute of Neurological Disorders and Stroke, emphasized the degree to which the Neurobiology of Disease in Children conference series has broadened awareness of the many rare diseases affecting children, not only through the advancement of research but also by educating practitioners about diagnostic strategies. Dr Landis also discussed the role this conference may play in fostering research that seeks to develop a single mechanism of therapy for spinal muscular atrophy. She also discussed the current funding situation at the National Institutes of Health and addressed the crucial function of volunteer research organizations that sponsor research in further improving management of this condition. This article summarizes the presentations and includes the verbatim edited transcript of question-and-answer sessions.
AB - Spinal muscular atrophy is an autosomal recessive neurodegenerative disorder that affects the motor neurons responsible for movement of the proximal muscles of the trunk and body. To date, the disease can be classified into 3 main categories based on severity and age of onset. During the October 18th symposium held in Pittsburgh, Pennsylvania, researchers met to (1) describe current diagnostic strategies, (2) discuss recent thoughts on pathogenesis, (3) review current therapies and clinical trials, and (4) define future research directions. In her opening remarks, Dr Story Landis, director of the National Institute of Neurological Disorders and Stroke, emphasized the degree to which the Neurobiology of Disease in Children conference series has broadened awareness of the many rare diseases affecting children, not only through the advancement of research but also by educating practitioners about diagnostic strategies. Dr Landis also discussed the role this conference may play in fostering research that seeks to develop a single mechanism of therapy for spinal muscular atrophy. She also discussed the current funding situation at the National Institutes of Health and addressed the crucial function of volunteer research organizations that sponsor research in further improving management of this condition. This article summarizes the presentations and includes the verbatim edited transcript of question-and-answer sessions.
KW - Clinical features
KW - Future research directions
KW - Pathogenesis
KW - Spinal muscular atrophy
UR - http://www.scopus.com/inward/record.url?scp=34548165592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548165592&partnerID=8YFLogxK
U2 - 10.1177/0883073807305662
DO - 10.1177/0883073807305662
M3 - Article
C2 - 17761647
AN - SCOPUS:34548165592
SN - 0883-0738
VL - 22
SP - 926
EP - 945
JO - Journal of Child Neurology
JF - Journal of Child Neurology
IS - 8
ER -